home button
H.I.G. logo
about us

At H.I.G. Ventures, we partner with entrepreneurs to provide the capital, expertise and relationships necessary to build market-leading businesses. With over $550 million in dedicated venture capital under management, we invest nationally in the following types of companies:

H.I.G. has over $7.5 billion of capital under management through five fund vehicles:  venture and growth capital, lower middle market LBO, European LBO, a debt fund and a public equity hedge fund.  The firm is generally considered one of the most active and successful middle market private equity franchises, consistently ranked in the top 5% of private equity firms in terms of performance.  H.I.G. has invested in and managed more than 200 companies with combined sales in excess of $7 billion.

H.I.G.’s team of seasoned managing directors takes an active role in the development of each portfolio company, bringing a wealth of operating, consulting, technology and financial management expertise to the table. The firm has a strong track record of building competitive businesses and creating significant value for shareholders.

We have built that track record by:

  • Helping founders find and recruit top talent
  • Providing marketing and strategic positioning expertise
  • Providing business development and strategic introductions
  • Helping to raise additional capital
  • Providing in-house legal counsel

H.I.G. has venture capital offices in Atlanta and Miami. Worldwide, H.I.G. has over 150 investment professionals with additional offices in Boston, San Francisco, London, Hamburg and Paris.

 

 
about us image
ask the C.E.O.


“Tranzyme Pharma was in a preclinical stage when we approached H.I.G. for funding.  Not many investors would consider companies at such and early stage, but H.I.G. understood the market and the need for innovative products that treat gastrointestinal and metabolic diseases and took the risk.  One year after the financing, we have successfully completed a Phase I trial of our lead product and anticipate having a second candidate in the clinic by 2007.”

- Vipin K. Garg, Ph.D., President and CEO, Tranzyme Pharma

HIGVentures.com - All material on this site Copyright © 2006 H.I.G. Ventures